Medication info
Starpogil 5/80 Milligrams

Starpogil 5/80 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tablet
Manufacturer / importer
Hwanin Pharmaceutical Co., Ltd.
Appearance
Dark yellow round film-coated tablets
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Active

MFDS item code 201308483 · Approved 2013.07.30 · Insurance code 657202560

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
The recommended dose is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components as described below, switching directly to this medicine may be considered. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years or older: Use caution when increasing the dose.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Ingredients

Manufacturer
Hwanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or valsartan.

How to take

Adult dose

The recommended dose is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using the individual components as described below, switching directly to this medicine may be considered. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. Do not administer this medicine to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years or older: Use caution when increasing the dose.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus and neonate if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to those who are allergic to this medication or components of similar classes, pregnant or potentially pregnant women, nursing mothers, patients with severe renal or liver impairment, and those with certain heart diseases. Patients with low sodium or fluid levels in the body should correct their status before taking this medication, and if hypotension occurs, they should lie down immediately and receive intravenous therapy if necessary. Those with high potassium levels or taking potassium supplements should frequently monitor potassium levels. Patients with renal vascular issues, kidney transplant recipients, or a history of angioedema should exercise particular caution when taking this medication. Patients with heart failure or those recovering from a myocardial infarction should frequently monitor renal function and blood pressure when taking this medication. Caution is also warranted for patients with acute myocardial infarction or certain valvular heart diseases. When taken with other antihypertensive medications, this medication may increase the risk of hypotension, worsening renal function, or hyperkalemia, so regular blood pressure and laboratory tests are required as per doctor's guidance. Dizziness or fatigue may occur while driving or operating machinery; caution is advised. Overdose may lead to hypotension and cardiac dysfunction, so immediate medical attention is required if symptoms occur. This medication is not recommended for children under the age of 18, as its safety and efficacy have not been established.

Side effects

nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional dizziness, paresthesia, lightheadedness, tinnitus, tachycardia, palpitations, fainting, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, itching, joint swelling, low back pain, arthritis, muscle cramps, lethargy, polyuria, nocturia, erectile dysfunction, edema, peripheral edema, facial edema, generalized edema, fatigue, flushing, asthenia, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, vascular edema, myalgia, renal failure, renal impairment, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, sensory loss, dysgeusia, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, vascular edema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, urination disorder, nocturnal enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, elevated liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, neurosensitivity, sensory loss, Stevens-Johnson syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Dark yellow round film-coated tablets

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.